|
|
|
European Pharmaceutical Contractor
|
|
Outsourcing of pharmaceutical development and manufacturing processes has been a constantly growing business segment for a couple of years now, in the area of investigational product supply as well as in commercial production. While the pharmaceutical industry faces a decline in their product pipelines and expiring patents, it has started to concentrate on marketing and sales alongside research and development activities, and has begun to intensify outsourcing of all other processes. With tactical or short-term outsourcing still the predominant tendency, sponsor companies mainly gain only from short-term benefits. As speed to market is one of the crucial factors for the future prospects of pharmaceutical companies, a combination of strategic and tactical outsourcing provides the means to overcome existing challenges.
Subcontracting a process, such as product design or manufacturing, to a third-party company has been observed since the 1960s, when technologically simple manufacturing processes such as production of clothes were transferred to contract manufacturers in Asia. Outsourcing became part of the business lexicon during the 1980s, when companies like General Motors or Eastman Kodak started outsourcing their IT processes and structures (1). Often driven by cost restrictions, outsourcing was publicly linked to job transfer and job destruction, thus superseding efforts to make better use of time and energy costs, or to make more efficient use of labour, capital, (information) technology and resources.
Outsourcing may seem difficult, especially for more complex processes, such as those in the pharmaceutical supply chain. Looking at the inherent conflict of interest in any outsourcing arrangement, getting better service at lower costs versus the vendor’s target to make profit, a successful outcome for both client and vendor strongly depends on the management and co-operation abilities of both parties.
This paper will therefore focus on the conditions that pharmaceutical companies are facing today, and when and how outsourcing could be a useful tool to respond to current and future challenges. |
Read full article from PDF >>
|
 |
 |
 |
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
Claudio A Lorck started his career in pharmaceutical development, where he was concerned with formulation development and production transfer of sustained release pellet formulations for five years. For the following seven years he was QC Manager with responsibility for all QC laboratories and deputised the Director QC. In October 2005 he became Head of Clinical Trial Materials and QP at Astellas Deutschland GmbH, and from January 2007 on at Temmler Werke GmbH, when the site was sold from Astellas to Temmler. He has gained wide experience with outsourcing from the point of view of a sponsor as well as that of a vendor company.
Arnim Laicher began work in Pharmaceutical Development, where he was concerned with formulation development of solid dosage forms. Between 1985 and 2001, he was Head of Dosage Form Development and later Director of Pharmaceutical Development at Klinge Pharma GmbH, with responsibility for NCE development, scale-up and production transfer. In 2002, he took responsibility for an outsourcing project at Fujisawa Deutschland GmbH, before becoming Head of Quality Assurance at Fujisawa GmbH and later Astellas Pharma GmbH until December 2006, and from January 2007 on at Temmler Werke GmbH. He has wide experience in outsourcing, as well as in auditing contract manufacturers (APIs, excipients, drug product manufacture, distribution and quality control). |
|
 |
 |
 |
|

 |
Industry Events |
 |
PHASE II & IIa Clinical Trials
21-22 February 2012, Lancaster London Hotel, London
Learn how to overcome challenges in adapting the development process to achieve early Proof of Concept at Informa's 13th Annual Phase I & IIa Clinical Trials event.
More info >> |
|
 |
News and Press Releases |
 |
Pantec Biosolutions to Present P.L.E.A.S.E.® Professional for Transdermal Drug Delivery at DDP in Las Vegas
Pantec Biosolutions AG, the developer and manufacturer of P.L.E.A.S.E.® Professional, a state of the art portable laser device that sets new standards for safety, precision and versatility, today announced that it will be giving a scientific company presentation during the “Drug Delivery Partnerships” conference from 25th -27th January 2012 in Las Vegas, USA.
More info >> |
|
|